IN8bio, Inc. (INAB)Healthcare | Biotechnology | New York, United States | NasdaqCM
1.04 USD
0.00
(-0.481%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.04 +0.01 (0.821%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:15 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish despite a recent bounce, as the stock trades at a significant discount to its moving averages and faces a weak statistical forecast. While the price has rallied from $0.96 to $1.28 over the last two weeks, it remains well below the 200-day average, suggesting the recovery is fragile rather than a trend reversal. The statistical model offers no directional edge, reflecting the high volatility typical of biotech names. From a long-term perspective, the investment case is severely compromised by a catastrophic multi-year decline. The business has lost 99% of its value over the past four years, with every single year showing negative returns. This consistent annual deterioration indicates a structural failure in the company's ability to generate value or navigate its clinical pipeline effectively, overriding any optimism regarding specific drug trials or analyst price targets. The market has clearly priced out the risk of continued failure. There is no income component to this investment; the company has not paid a dividend in the last five years, offering no cushion against the capital loss risks inherent in a speculative biotech firm with negative earnings and cash flow. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.129729 |
| AutoARIMA | 0.147504 |
| AutoETS | 0.147508 |
| MSTL | 0.153991 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 22.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.213 |
| Excess Kurtosis | -1.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.855 |
| Market Cap | 10,203,426 |
| Forward P/E | -1.07 |
| Beta | 0.28 |
| Website | https://in8bio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5294118 |
| Address1 | 350 5th Avenue |
| Address2 | Suite 5330 |
| All Time High | 309.57 |
| All Time Low | 0.88 |
| Ask | 1.33 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 60,520 |
| Average Daily Volume3 Month | 60,151 |
| Average Volume | 60,151 |
| Average Volume10Days | 60,520 |
| Beta | 0.28 |
| Bid | 0.7488 |
| Bid Size | 2 |
| Book Value | 1.864 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.035 |
| Current Ratio | 8.206 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.05 |
| Day Low | 1.03 |
| Debt To Equity | 11.855 |
| Display Name | IN8bio |
| Earnings Timestamp End | 1,754,596,800 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda | -17,797,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.313 |
| Enterprise Value | -5,575,573 |
| Eps Current Year | -1.0875 |
| Eps Forward | -0.965 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.23586 |
| Fifty Day Average Change | -0.20086002 |
| Fifty Day Average Change Percent | -0.16252652 |
| Fifty Two Week Change Percent | -52.941177 |
| Fifty Two Week High | 2.73 |
| Fifty Two Week High Change | -1.695 |
| Fifty Two Week High Change Percent | -0.6208791 |
| Fifty Two Week Low | 0.88 |
| Fifty Two Week Low Change | 0.15499997 |
| Fifty Two Week Low Change Percent | 0.17613633 |
| Fifty Two Week Range | 0.88 - 2.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 7,190,606 |
| Forward Eps | -0.965 |
| Forward P E | -1.0725389 |
| Free Cashflow | -7,915,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Fullday Change | -0.005 |
| Fullday Change Percent | -0.480769 |
| Fullday Price | 1.0435 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07577 |
| Held Percent Institutions | 0.38445 |
| Implied Shares Outstanding | 9,858,383 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,749,168,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. |
| Long Name | IN8bio, Inc. |
| Market | us_market |
| Market Cap | 10,203,426 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_556676116 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -18,667,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,328,627 |
| Number Of Analyst Opinions | 4 |
| Open | 1.04 |
| Operating Cashflow | -14,355,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 646 600 6438 |
| Post Market Change | 0.00849998 |
| Post Market Change Percent | 0.82125413 |
| Post Market Price | 1.0435 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 1.04 |
| Price Eps Current Year | -0.9517241 |
| Price Hint | 4 |
| Price To Book | 0.5552575 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.966 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.004999995 |
| Regular Market Change Percent | -0.48076877 |
| Regular Market Day High | 1.05 |
| Regular Market Day Low | 1.03 |
| Regular Market Day Range | 1.03 - 1.05 |
| Regular Market Open | 1.04 |
| Regular Market Previous Close | 1.04 |
| Regular Market Price | 1.035 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 23,999 |
| Return On Assets | -0.58374 |
| Return On Equity | -1.11106 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,858,383 |
| Shares Percent Shares Out | 0.014199999 |
| Shares Short | 139,903 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 20,789 |
| Short Name | IN8bio, Inc. |
| Short Percent Of Float | 0.0159 |
| Short Ratio | 1.92 |
| Source Interval | 15 |
| State | NY |
| Symbol | INAB |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.5 |
| Total Cash | 17,956,000 |
| Total Cash Per Share | 1.821 |
| Total Debt | 2,177,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.61834 |
| Two Hundred Day Average Change | -0.58334005 |
| Two Hundred Day Average Change Percent | -0.3604558 |
| Type Disp | Equity |
| Volume | 23,999 |
| Website | https://in8bio.com |
| Zip | 10,118 |